Molecular Biometrics, Inc. is applying novel metabolomic technologies to develop accurate, non-invasive clinical tools for use in personalized medicine to evaluate normal biologic function in health and in disease, and for drug discovery and development. The company’s lead product, ViaMetrics-E™, is a diagnostic procedure designed to help identify the most viable embryos with the greatest reproductive potential for in vitro fertilization (IVF). The company’s proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease). Molecular Biometrics is currently headquartered in Chester, NJ, however, intends to relocate to the Boston area in early 2009. In addition, Molecular Biometrics has R&D facilities in New Haven, CT, and Montreal, Quebec.
The availability of Molecular Biometrics’ ViaMetrics-E will be revolutionary for the 7.3 million people in the United States, and the millions of others worldwide who are affected by infertility. This technology will fulfill an unmet medical need and is well positioned to tap into the $4 billion global IVF market. ViaMetrics-E is intended to provide increased accuracy when assessing the viability of an embryo for insemination through IVF. ViaMetrics-E may hold significant potential to increase IVF success rates, while minimizing the number IVF cycles required to achieve a live birth. ViaMetrics-E could also provide physicians with a procedure that may reduce the incidence, costs, and medical risk associated with multiple births, which constitute more than one-third of births under current IVF methods. Currently, the annual number of assisted reproductive technologies (ART) cycles, with the majority being IVF, exceeds 1 million worldwide. Each ART cycle in the U.S. costs between $10,000 and $15,000. The ability to reduce the number of IVF cycles and the complications associated with multiple births could result in substantial savings to the overall healthcare system.
Website:
www.molecularbiometrics.com
Safeguard Partner Company since 2008